Therapeutic DNP derivatives and methods using same
The present invention includes DNP derivatives that are useful for preventing or treating a metabolic disease or disorder in a subject in need thereof. In certain embodiments, the subject is further administered at least one additional therapeutic agent.
1. A compound selected from the group consisting of:
N-(2-hydroxy-3,5-dinitrobenzyl)-4-mercaptobutanamide,
2-(1-hydroxypropyl)-4,6-dinitrophenol,
4-(2,4-dinitrophenoxy)pentan-2-ol,
3-(2,4-dinitrophenoxy) cyclohexanol,
2,4-dinitrophenyl dihydrogen phosphate,
3-((4-((2,4-dinitrophenoxy)methyl)phenyl)disulfanyl) propanoic acid,
3-((4-((((4-((2,4-dinitrophenoxy)methyl)phenyl)carbamoyl)oxy)methyl)phenyl) disulfanyl)propanoic acid, and
(R)-4-((3R,5R,7R,8R,9S,10 S,12S,13R,14S,17S)-3-(2-(3-((4-((2,4-dinitrophenoxy)methyl)phenyl)disulfanyl)propanamido)ethoxy)-7,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid.
2. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and a compound selected from the group consisting of:
N-(2-hydroxy-3,5-dinitrobenzyl)-4-mercaptobutanamide,
2-(1-hydroxypropyl)-4,6-dinitrophenol,
4-(2,4-dinitrophenoxy)pentan-2-ol,
3-(2,4-dinitrophenoxy) cyclohexanol,
2,4-dinitrophenyl dihydrogen phosphate,
3-((4-((2,4-dinitrophenoxy)methyl)phenyl)disulfanyl) propanoic acid,
3-((4-((((4-((2,4-dinitrophenoxy)methyl)phenyl)carbamoyl)oxy)methyl)phenyl) disulfanyl)propanoic acid, and
(R)-4-((3R,5R,7R,8R,9S,10S,12S,13R,14S,17S)-3-(2-(3-((4-((2,4-dinitrophenoxy)methyl)phenyl)disulfanyl)propanamido)ethoxy)-7,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid.
3. The pharmaceutical composition of claim 2 , further comprising at least one additional therapeutic agent.
4. The pharmaceutical composition of claim 2 , wherein the compound is present in an amount of about 1 mg to about 500 mg.
5. The pharmaceutical composition of claim 2 , wherein the composition is in the form of tablets, dragees, liquids, drops, suppositories, or capsules, caplets, or gelcaps.
6. The pharmaceutical composition of claim 5 , wherein the tablet comprises a multi-layered delayed release tablet.